Financial news for CLTX dated on 2015-09-21: Akari Therapeutics 13G Filing Shows Deerfield Mgmt Holds 9.77% Stake As Of Sept 18

Financial news for CLTX dated on 2015-09-21: Deerfield Leads Funding in Creation of Akari Therapeutics

Financial news for CLTX dated on 2015-09-10: Celsus Therapeutics CEO Gur Roshwalb, MD Tells Benzinga via Email there is No News to Account for Move in the Stock Today

Financial news for CLTX dated on 2015-09-10: Celsus Therapeutics +21%

Financial news for CLTX dated on 2015-08-31: Celsus Therapeutics Spikes Higher on Volume

Financial news for CLTX dated on 2015-08-19: UPDATE: Celsus Therapeutics Spike to High +170%

Financial news for CLTX dated on 2015-08-19: Celsus Therapeutics Shares +145%

Financial news for CLTX dated on 2015-08-19: Celsus Therapeutics Spikes Higher

Financial news for CLTX dated on 2015-08-18: Celsus Therapeutics +96% Premarket as Celsus, Volution Immuno Pharmaceuticals Announce \$75M Private Placement

Financial news for CLTX dated on 2015-07-13: Shares of Celsus Therapeutics to Resume Trade at 7:45 p.m. ET

Financial news for CLTX dated on 2015-07-13: UPDATE: Celsus Says New Combined Co. Will Begin Phase II Trials for Several Indications (PNH, GBS, AHUS) in '16

Financial news for CLTX dated on 2015-07-13: UPDATE: Celsus Therapeutics Says Volution to Become Wholly-Owned Unit of Co., Current Holders Will Own  $\sim 8.32\%$  of Combined Co.

Financial news for CLTX dated on 2015-07-13: UPDATE: Upon Closing of Celsus Therapeutics, Volution Deal, Co. to be Renamed Akari Therapeutics

Financial news for CLTX dated on 2015-07-13: Celsus Therapeutics, Volution Immuno Pharmaceuticals Agree to Create Orphan Disease Company Focused on Complement C5 Inhibition

Financial news for CLTX dated on 2015-07-13: Celsus Therapeutics Shares Halted News Pending

Financial news for CLTX dated on 2015-03-31: Stocks Hitting 52-Week Lows

Financial news for CLTX dated on 2015-02-17: Celsus Therapeutics' Lead Drug Flunks Phase II Trial

Financial news for CLTX dated on 2015-02-17: Stocks Hitting 52-Week Lows

Financial news for CLTX dated on 2015-02-17: Morning Market Losers

Financial news for CLTX dated on 2015-02-17: Celsus Therapeutics Shares Fall 83% on Failed Phase 2 MRX-6 Cream Trial

Financial news for CLTX dated on 2015-02-17: Celsus Therapeutics Announces Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Meet Primary Endpoint

Financial news for CLTX dated on 2015-01-13: Celsus Therapeutics Reports Closing of Enrollment for Phase II Trial of MRX-6 Cream 2%

Financial news for CLTX dated on 2015-01-12: Celsus Therapeutics Announces FDA Allowance of Investigational New Drug Application For MRX-6

Financial news for CLTX dated on 2014-09-04: Morning Market Movers

Financial news for CLTX dated on 2014-08-13: Celsus Therapeutics Files For Up to \$75M Mixed Shelf

Financial news for CLTX dated on 2014-08-13: Filing from Celsus Therapeutics Shows Registration for \$75M ADS Shelf Offering

Financial news for CLTX dated on 2014-08-06: Celsus Therapeutics Says First Patient Enrolled in Phase II MRX-6 rial

Financial news for CLTX dated on 2014-06-17: Celsus Receives Approval For Phase II MRX-6 Trial From Israeli Government

Financial news for CLTX dated on 2014-03-11: Celsus Therapeutics To Advance Phase II Trials in MRX-6

Financial news for CLTX dated on 2014-01-30: Celsus Therapeutics Prices 1.33M ADS Offering at \$6.00/ADS; Announces Nasdaq Listing